Cardio Diagnostics Holdings, Inc.

NasdaqCM CDIO

Cardio Diagnostics Holdings, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 646.57

Cardio Diagnostics Holdings, Inc. Price to Sales Ratio (P/S) is 646.57 on January 14, 2025, a 91.73% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Cardio Diagnostics Holdings, Inc. 52-week high Price to Sales Ratio (P/S) is 1,722.39 on December 11, 2024, which is 166.39% above the current Price to Sales Ratio (P/S).
Cardio Diagnostics Holdings, Inc. 52-week low Price to Sales Ratio (P/S) is 337.22 on December 04, 2024, which is -47.84% below the current Price to Sales Ratio (P/S).
Cardio Diagnostics Holdings, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 1,015.17.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqCM: CDIO

Cardio Diagnostics Holdings, Inc.

CEO	Dr. Meeshanthini V. Dogan Ph.D.
IPO Date	Jan. 14, 2022
Location	United States
Headquarters	400 N Aberdeen St
Employees	7
Sector	Health Care
Industries Clinical Trials Biotechnology

Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Key trends

Past 5 years